The dose-limiting salivary gland toxicity of 225 Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A 68 Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.
A 63-year-old patient with advanced metastatic castrationresistant prostate cancer underwent 68 Ga-PSMA PET/CT imaging before and 45 days after receiving multifocal, ultrasound-guided injections of a total of 80 units botulinum toxin A into the right parotid gland (Fig. 1) according to a clinically approved method used in patients who have suffered from sialorrhoea for over two decades [1] [2] [3] . The SUVmean of the radioligand in the injected parotid gland showed a highly significant decrease of up to 60% compared with the left side, especially in the pars profunda of the gland, and a decrease of up to 64%, but no significant change in the left parotid gland, compared with the baseline PET/CT study. At the time of this report, after a follow-up of 3 months, the patient had not reported any adverse effects of the injections. The impressive decrease in PSMA radioligand uptake in the salivary glands, which is described here for the first time, could be a significant breakthrough for salivary gland protection, which is highly needed in the context of targeted alpha therapy using 213 Bi-PSMA and 225 Ac-PSMA [4, 5] .
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